Conversion from mild cognitive impairment to dementia: Influence of folic acid and vitamin B12 use in the vita cohort
Increased serum homocysteine and low folate levels are associated with a higher rate of conversion to dementia. This study examined the influence of vitamin B12/folic acid intake on the conversion from mild cognitive impairment (MCI) to dementia.
A community dwelling cohort of older adults (N=81) from the Vienna Transdanube aging study with MCI.
Prospective study with a retrospective evaluation of vitamin intake.
Laboratory measurements, brain magnetic resonance imaging, and cognitive functioning were assessed at baseline and at five-year follow-up.
The self-reported combined use of folic acid and vitamin B12 for more than one year was associated with a lower conversion rate to dementia. Serum levels of homocysteine and vitamin B12 as measured at baseline or at five years were not associated with conversion. Higher folate levels at baseline in females predicted a lower conversion rate to dementia. The assessment of brain morphological parameters by magnetic resonance imaging revealed higher serum folate at baseline, predicting lower medial temporal lobe atrophy and higher levels of homocysteine at baseline, predicting moderate/severe global brain atrophy at five years. Users of vitamin B12 or folate, independent of time and pattern of use, had lower grades of periventricular hyperintensities and lower grades of deep white matter lesions as compared to non-users.
These results from a middle european study support observations on the protective ability of folate in MCI patients with respect to conversion to dementia; they also point to a participation of homocysteine metabolism on processes associated with brain atrophy.
Key wordsFolic acid vitamin B12 homocysteine mild cognitive impairment dementia
Unable to display preview. Download preview PDF.
- 4.Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA. 1983 Jun 3:249:2917–21.Google Scholar
- 8.Malouf R, Grimley EJ. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev. 2008;CD004514.Google Scholar
- 9.Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5:el2244.Google Scholar
- 10.de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry. 2011 Jul 21.Google Scholar
- 11.Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragi KH, Fischer P. Conversion from cognitive health to mild cognitive impairment and Alzheimer’s disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging. 2008 Jan;29:1–11.PubMedCrossRefGoogle Scholar
- 12.Fischer P, Jungwirth S, Krampla W, Weissgram S, Kirchmeyr W, Schreiber W, Huber K, Rainer M, Bauer P, Tragi KH. Vienna Transdanube Aging “VITA”: study design, recruitment strategies and level of participation. J Neural Transm Suppl. 2002;105–116.Google Scholar
- 14.Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004 Sep;256:240–246.PubMedCrossRefGoogle Scholar
- 17.Berres M, Monsch AU, Bernasconi F, Thalmann B, Stahelin HB. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer’s disease. Stud Health Technol Moral. 2000;77:195–199.Google Scholar
- 18.Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills. 1958;8:271–276.Google Scholar
- 19.McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984 Jul;34:939–944.PubMedCrossRefGoogle Scholar
- 22.Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Worlshop. Neurology. 1993 Feb;43:250–260.Google Scholar
- 23.Fischer P, Krampla W, Mostafaie N, Zehetmayer S, Rainer M, Jungwirth S, Huber K, Bauer K, Hruby W, et al. VITA study: white matter hyperintensities of vascular and degenerative origin in the elderly. J Neural Transm Suppl. 2007;181–188.Google Scholar
- 30.Huber KR, Mostafaie N, Stangl G, Worofka B, Kittl E, Hofmann J, Hejtman M, Michael R, Weissgram S, et al. Clinical chemistry reference values for 75-year-old apparently healthy persons. Clin ChemLabMed. 2006;44:1355–1360.Google Scholar
- 39.Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, Jacques PF, Yoshita M, Rosenberg IH, D’Agostino RB, DeCarli C. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol. 2008 May;65:642–649.PubMedCrossRefGoogle Scholar